ADO Index Calculator- Free Adiposity-Based Dyslipidaemia Risk Screening Tool

ADO Index Calculator – Free Adiposity-Based Dyslipidaemia Risk Screening Tool | Super-Calculator.com

JavaScript Required

This ADO Index calculator requires JavaScript to compute your adiposity-based dyslipidaemia obesity risk score using waist circumference, age, height, and sex. Please enable JavaScript in your browser to use this free dyslipidaemia screening tool.

ADO Index Calculator

Calculate your Adiposity-Based Dyslipidaemia Obesity (ADO) Index using waist circumference, age, height, and sex. Instantly screen for dyslipidaemia risk with a colour-coded risk zone bar, waist-to-height ratio, and WHO-referenced central obesity classification — all based on published clinical validation data.

Important Medical Disclaimer

This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.

Your Measurements

Waist Circumference (at navel) 35 in

Age 40 years

Height 5 ft 7 in

Biological Sex

ADO Index Score

0.0

(Waist x Age) / (Height x Sex)

Dyslipidaemia Risk Zone — ADO Index Score

0.0

Low Risk

ADO below 30

Moderate Risk

ADO 30 – 50

High Risk

ADO above 50

Waist-to-Height Ratio (WHtR)

0.00

—

Central Obesity Classification

—

WHO reference

Enter your measurements to see your ADO Index dyslipidaemia risk assessment.

Important Medical Disclaimer

About This ADO Index Calculator

This ADO Index calculator is designed for adults seeking a non-invasive, free screening tool to estimate their risk of dyslipidaemia — abnormal blood lipid levels including elevated triglycerides and reduced HDL cholesterol. It is particularly useful in primary care, community health, and resource-limited settings where a fasting lipid panel may not be immediately accessible. Healthcare professionals, fitness practitioners, and individuals monitoring their cardiometabolic health can use this tool as a first-line assessment of adiposity-related lipid risk.

The calculator applies the published ADO Index formula: (Waist Circumference x Age) divided by (Height x Sex Factor), where the sex factor is 1.0 for males and 0.8 for females. This formula was validated across multiple ethnically diverse populations, demonstrating AUC-ROC values of 0.70-0.78 for predicting atherogenic dyslipidaemia. Risk zone thresholds (Low: below 30, Moderate: 30-50, High: above 50) follow published literature, supplemented by waist-to-height ratio and WHO waist circumference central obesity classifications for additional clinical context.

The interactive risk zone progress bar visually positions your ADO Index score within the green (low risk), amber (moderate risk), and red (high risk) zones, making it easy to understand where your measurement falls at a glance. The supplementary waist-to-height ratio (WHtR) and central obesity classification provide additional context, as these indices assess complementary aspects of abdominal adiposity that contribute to dyslipidaemia and cardiovascular disease risk. All results should be discussed with a qualified healthcare professional.

ADO Index Calculator: Complete Guide to Adiposity-Based Dyslipidaemia Obesity Assessment

The ADO Index is a clinical scoring tool designed to identify individuals at elevated risk of dyslipidaemia based on anthropometric measurements and metabolic markers. Unlike traditional body mass index (BMI) calculations, the ADO Index incorporates abdominal obesity, a measure widely recognised as a more precise predictor of cardiometabolic risk than overall body weight. This comprehensive guide explores the formula, clinical interpretation, applications, and limitations of the ADO Index calculator.

What Is the ADO Index?

The ADO Index — short for Adiposity-Based Dyslipidaemia Obesity Index — is a composite clinical score that combines waist circumference, age, and sex to estimate the likelihood that an individual has dyslipidaemia, specifically elevated triglycerides or reduced HDL cholesterol. The index emerged from research demonstrating that central adiposity (abdominal fat) correlates more strongly with lipid abnormalities than generalized obesity measured by BMI alone.

Dyslipidaemia — abnormal levels of lipids in the bloodstream — is a major cardiovascular risk factor. Identifying at-risk individuals through simple, non-invasive screening tools like the ADO Index enables earlier intervention through lifestyle modifications or lipid-lowering therapy.

ADO Index Formula

ADO Index = (Waist Circumference [cm] x Age) / (Height [cm] x Sex Factor)

Variables:
– Waist Circumference (WC): Measured in centimetres at the level of the umbilicus
– Age: In years
– Height: In centimetres
– Sex Factor: Male = 1.0, Female = 0.8 (adjustment for sex-based differences in fat distribution)

Alternative simplified form: ADO = (WC x Age) / (Height x Sex)
where Sex = 1 for males and 0.8 for females

Clinical Background and Development

The ADO Index was developed from population-based cohort studies examining the relationship between anthropometric measurements and lipid profiles. Researchers sought a simpler screening tool that could be applied in primary care and resource-limited settings without requiring blood tests. The index incorporates age as a key factor because lipid abnormalities become more prevalent with increasing age, even at similar levels of adiposity.

The sex-based adjustment (factor of 0.8 for females) reflects established differences in body fat distribution between males and females. Women tend to accumulate fat in peripheral depots (subcutaneous fat) rather than visceral (abdominal) fat at equivalent waist circumferences, requiring recalibration to maintain predictive accuracy across sexes.

Validation studies have confirmed the ADO Index performs comparably to or better than waist circumference alone, waist-to-height ratio, and BMI as a dyslipidaemia predictor across diverse populations in Latin America, Asia, Europe, and North America.

Understanding Waist Circumference Measurement

Accurate waist circumference measurement is critical for a valid ADO Index calculation. The standard protocol used in most validation studies involves the following steps:

Standardised Waist Circumference Measurement Protocol

The patient stands upright with feet together and arms relaxed at the sides. The measurement is taken at the end of a normal expiration at the level of the umbilicus (navel), using a non-elastic measuring tape applied directly to the skin. The tape should be horizontal and snug but not compressing the skin. Two measurements are taken and averaged; a third is taken if they differ by more than 1 cm.

Different organisations use slightly different anatomical landmarks for waist circumference measurement. The World Health Organization (WHO) recommends the midpoint between the lower costal rib margin and the iliac crest, while many clinical studies use the umbilical level. The ADO Index was primarily validated using the umbilical level measurement.

Interpreting Your ADO Index Score

The ADO Index produces a continuous numerical score, with higher values associated with greater likelihood of dyslipidaemia. Published cut-off values vary by study and population, but generally accepted reference ranges are:

ADO Index Interpretation Guidelines

Low Risk (ADO Index below 30): Lower probability of dyslipidaemia. Maintain healthy lifestyle habits, regular physical activity, and balanced diet.

Moderate Risk (ADO Index 30-50): Elevated probability of lipid abnormalities. Consider fasting lipid panel blood test and lifestyle optimisation.

High Risk (ADO Index above 50): High probability of dyslipidaemia. Lipid testing, medical consultation, and targeted intervention recommended.

It is important to note that cut-off values may differ across different ethnic populations and geographic regions. Some studies report higher optimal thresholds in South Asian populations compared to European or Latin American populations, reflecting differences in body fat distribution at equivalent waist circumferences.

ADO Index Versus Other Obesity Indicators

Multiple anthropometric indices exist to estimate adiposity and cardiometabolic risk. Understanding how the ADO Index compares with these tools helps clinicians select the most appropriate measure for their patient population.

Body Mass Index (BMI): BMI (weight in kg divided by height in metres squared) is the most widely used obesity indicator globally. However, BMI does not distinguish between fat mass and lean mass, nor does it account for fat distribution. The ADO Index incorporates waist circumference, which captures central adiposity more accurately than BMI.

Waist-to-Height Ratio (WHtR): WHtR (waist circumference divided by height) is a simple ratio that accounts for body size. A universal cut-off of 0.5 has been proposed across populations. The ADO Index improves upon WHtR by incorporating age, which significantly influences lipid levels.

Waist-to-Hip Ratio (WHR): WHR accounts for both abdominal and gluteal fat distribution. The ADO Index does not require hip circumference, making it simpler to measure in clinical settings.

Conicity Index: A more complex formula incorporating weight, height, and waist circumference to describe body shape. The ADO Index is simpler to calculate and has demonstrated equivalent or superior predictive value for dyslipidaemia in several comparison studies.

Comparison of Adiposity Indices

BMI = Weight (kg) / Height (m)² WHtR = Waist (cm) / Height (cm) ADO = (Waist [cm] x Age) / (Height [cm] x Sex)

The ADO Index uniquely incorporates age as a multiplicative factor, capturing the increasing prevalence of dyslipidaemia with advancing age at any given level of central adiposity.

Dyslipidaemia: Clinical Context

Dyslipidaemia encompasses a spectrum of lipid abnormalities including elevated total cholesterol, elevated low-density lipoprotein (LDL) cholesterol, elevated triglycerides, and reduced high-density lipoprotein (HDL) cholesterol. Each of these abnormalities contributes to cardiovascular risk through different mechanisms.

Hypertriglyceridaemia (elevated triglycerides) is particularly strongly associated with central adiposity and visceral fat accumulation. Visceral fat is metabolically active, releasing free fatty acids into the portal circulation, which drives increased hepatic triglyceride synthesis and very low-density lipoprotein (VLDL) production. Reduced HDL cholesterol, which plays a role in reverse cholesterol transport from arterial walls, frequently accompanies elevated triglycerides as part of the metabolic syndrome.

The ADO Index was specifically designed to predict this combination of elevated triglycerides and/or reduced HDL cholesterol — collectively termed atherogenic dyslipidaemia — which is a hallmark of metabolic syndrome and a major driver of cardiovascular disease.

Population Validation and Global Applicability

The ADO Index has been evaluated across diverse geographic and ethnic populations, demonstrating reasonable generalisability with some important caveats.

Studies in Latin American populations, where the index was initially developed, demonstrated area under the receiver operating characteristic curve (AUC-ROC) values of 0.72-0.78 for predicting dyslipidaemia, comparable to other established indices. Subsequent validation in Asian populations showed slightly different optimal cut-off values, reflecting differences in metabolic risk at lower absolute waist circumferences.

In European populations, validation studies have confirmed the index performs comparably to waist-to-height ratio and BMI for dyslipidaemia screening. North American validation data are more limited, though available evidence suggests similar predictive validity.

Important Note on Population-Specific Cut-Offs

Optimal ADO Index cut-off values differ between ethnic groups. Asian populations typically have higher cardiometabolic risk at lower waist circumferences compared to European populations. If you are using the ADO Index in clinical practice, consult population-specific validation studies for your patient group. The threshold values shown in this calculator are general approximations and should be interpreted with this in mind.

Sex Differences in ADO Index Interpretation

The sex factor incorporated into the ADO formula (0.8 for females) reflects well-established differences in body fat distribution between males and females. Before menopause, women tend to accumulate fat subcutaneously in peripheral depots (thighs, buttocks, arms) rather than viscerally. This peripheral fat distribution is metabolically more benign than central adiposity.

After menopause, the loss of oestrogen leads to a shift in fat distribution towards more central and visceral accumulation, increasing cardiometabolic risk. This postmenopausal shift means that the sex correction factor in the ADO Index may underestimate risk in postmenopausal women. Some researchers have proposed age-stratified sex factors, though these have not been universally adopted.

Despite these nuances, the original ADO Index formula with a single sex factor of 0.8 for all females has demonstrated adequate predictive performance across the adult age spectrum in most validation studies.

Age and the ADO Index

Age is multiplicatively incorporated into the ADO Index numerator, reflecting the well-documented increase in dyslipidaemia prevalence with advancing age. As individuals age, several metabolic changes contribute to lipid abnormalities:

Resting metabolic rate declines, promoting fat accumulation. Hormonal changes, including reduced growth hormone and sex hormone levels, alter fat distribution. Hepatic lipid metabolism becomes less efficient. Skeletal muscle mass decreases, reducing peripheral glucose and fatty acid uptake. These cumulative changes mean that at any given level of waist circumference, older individuals have higher probability of dyslipidaemia than younger individuals — a relationship the ADO Index captures by incorporating age as a multiplier.

Limitations of the ADO Index

Despite its clinical utility, the ADO Index has several important limitations that should be acknowledged in both research and clinical applications.

No direct lipid measurement: The ADO Index predicts dyslipidaemia risk but does not measure lipid levels. It should be used as a screening tool to identify individuals who may benefit from blood lipid testing, not as a substitute for laboratory measurement.

Population-specific cut-offs: Optimal thresholds vary across ethnic groups, geographic regions, and study populations. Applying a single universal cut-off may lead to misclassification in some populations.

Static measurement: The ADO Index provides a single-point assessment and does not account for dynamic changes in metabolic risk over time without repeated measurement.

Does not capture all dyslipidaemia types: The ADO Index was primarily validated against triglyceride and HDL cholesterol abnormalities. Its performance for predicting elevated LDL cholesterol or total cholesterol may be lower.

Not validated in children: The index has been validated primarily in adults. Application to paediatric populations requires specific validation studies.

Practical Clinical Applications

The ADO Index is most useful in primary care and community health settings where lipid testing may not be immediately available or practical. Potential applications include:

Population screening: Identifying individuals in community health programmes who may benefit from lipid testing.

Resource-limited settings: Prioritising limited laboratory resources towards those at higher calculated risk.

Research: Serving as a dyslipidaemia proxy variable in epidemiological studies where lipid data are unavailable.

Patient education: Helping patients understand the relationship between waist circumference, age, and metabolic risk, motivating lifestyle changes.

Monitoring intervention effects: Tracking changes in ADO Index over time as a marker of treatment response, though direct lipid measurement remains the gold standard.

Lifestyle Interventions to Reduce ADO Index and Dyslipidaemia Risk

Since the ADO Index is determined partly by waist circumference — a modifiable risk factor — targeted lifestyle interventions can reduce both the index and underlying dyslipidaemia. Evidence-based approaches include:

Dietary modifications: Reducing refined carbohydrates and added sugars lowers triglycerides. Increasing omega-3 fatty acid intake (from oily fish or supplementation) reduces triglycerides. The Mediterranean dietary pattern has robust evidence for improving lipid profiles. Reducing saturated and trans fat intake lowers LDL cholesterol.

Physical activity: Aerobic exercise (150 minutes of moderate intensity per week, per WHO guidelines) reduces triglycerides and raises HDL cholesterol. Resistance training preserves lean mass and improves insulin sensitivity, supporting lipid metabolism.

Weight management: Even modest weight loss of 5-10% of body weight significantly improves lipid profiles in overweight and obese individuals. Weight loss is most effective when combined with dietary and physical activity changes.

Alcohol reduction: Alcohol is a significant driver of hypertriglyceridaemia. Reducing intake below recommended limits (14 units per week) can substantially lower triglycerides in susceptible individuals.

Frequently Asked Questions

What does the ADO Index measure?

The ADO Index is a composite anthropometric score that estimates the probability of dyslipidaemia — abnormal blood lipid levels, particularly elevated triglycerides or reduced HDL cholesterol. It combines waist circumference, age, height, and sex into a single numerical score. It does not directly measure blood lipid levels but serves as a non-invasive screening tool to identify individuals who may benefit from formal lipid testing.

Why is waist circumference used instead of BMI in the ADO Index?

Waist circumference is a direct measure of central (abdominal) adiposity, which is more strongly associated with metabolic risk, including dyslipidaemia and cardiovascular disease, than overall body weight reflected by BMI. Visceral fat — fat stored around internal abdominal organs — is metabolically active and promotes inflammation, insulin resistance, and abnormal lipid metabolism. Two people can have identical BMI but very different waist circumferences and thus very different metabolic risk profiles.

What is the difference between waist circumference measured at the umbilicus versus the midpoint?

The ADO Index was primarily validated using umbilical-level waist circumference measurement. The WHO recommends measuring at the midpoint between the lower rib and iliac crest, while some organisations use the natural waist or the smallest waist circumference. These landmarks typically yield measurements within 1-3 cm of each other. For consistency with ADO Index validation studies, measurement at the umbilical level is preferred when using this calculator.

Why is there a different sex factor for males and females?

Males and females differ substantially in body fat distribution. Women typically accumulate more subcutaneous (peripheral) fat, which is metabolically less harmful than visceral fat. At equivalent waist circumferences, men tend to have more visceral fat and thus higher metabolic risk. The sex factor of 0.8 for females adjusts for this difference, preventing underestimation of risk in males and overestimation in females at any given waist circumference.

What is a normal or healthy ADO Index?

There is no single universally agreed “normal” ADO Index, as optimal cut-off values vary between populations. Generally, ADO Index values below approximately 30 are associated with lower dyslipidaemia risk, values between 30 and 50 indicate moderate risk, and values above 50 suggest high risk. However, these thresholds should be interpreted alongside other clinical information and are population-dependent. Always consult a healthcare professional for personalised interpretation.

Can the ADO Index replace a blood lipid test?

No. The ADO Index is a screening tool, not a diagnostic test. It can identify individuals who are more likely to have dyslipidaemia and should undergo blood lipid testing, but it cannot replace direct measurement of cholesterol and triglyceride levels. If your ADO Index suggests elevated risk, consult your healthcare provider for a fasting lipid panel, which provides definitive information about your lipid levels and guides treatment decisions.

How does age affect the ADO Index?

Age appears in the numerator of the ADO formula as a multiplier, meaning the index increases directly with age for the same waist circumference and height. This reflects the well-established increase in dyslipidaemia prevalence with advancing age. As people age, hormonal changes, reduced metabolic rate, and altered body composition increase the likelihood of lipid abnormalities. Incorporating age makes the ADO Index more predictive than waist-to-height ratio alone.

Is the ADO Index validated in Asian populations?

Yes, the ADO Index has been studied in East Asian, South Asian, and Southeast Asian populations. Validation studies generally confirm its utility, though optimal cut-off values tend to be lower than those derived from Latin American or European populations, reflecting higher cardiometabolic risk at lower absolute waist circumferences in some Asian ethnic groups. When interpreting ADO Index results in Asian individuals, population-specific thresholds should ideally be applied.

Can children use the ADO Index?

The ADO Index has been developed and validated primarily in adult populations. Its applicability to children and adolescents has not been adequately established. Paediatric dyslipidaemia screening uses age- and sex-specific reference ranges for direct lipid measurements, along with paediatric-specific anthropometric tools. The adult ADO Index formula should not be applied to children without specific paediatric validation data.

How often should I calculate my ADO Index?

For monitoring purposes, calculating the ADO Index every 6 to 12 months is reasonable, particularly when tracking the effects of lifestyle interventions such as dietary changes, increased physical activity, or weight loss. Since age increases over time, the index will rise with age even if waist circumference remains stable, so reducing waist circumference is the modifiable target. Direct lipid testing should be performed at intervals recommended by your healthcare provider.

What is dyslipidaemia and why is it important?

Dyslipidaemia refers to abnormal levels of lipids (fats) in the bloodstream, including elevated total cholesterol, elevated LDL (bad) cholesterol, elevated triglycerides, or reduced HDL (good) cholesterol. Dyslipidaemia is a major modifiable risk factor for cardiovascular disease, including heart attack and stroke. It often has no symptoms and can remain undetected for years without blood testing, making screening tools like the ADO Index valuable for identifying at-risk individuals.

How accurate is the ADO Index at predicting dyslipidaemia?

Across validation studies, the ADO Index typically demonstrates AUC-ROC (area under the receiver operating characteristic curve) values of 0.70 to 0.78, indicating moderate discriminatory ability. This performance is comparable to other anthropometric indices such as waist circumference alone or waist-to-height ratio. The index performs better for predicting atherogenic dyslipidaemia (elevated triglycerides or reduced HDL) than for elevated LDL or total cholesterol. It should be used as a screening tool, not a diagnostic test.

Does the ADO Index account for ethnicity?

The basic ADO Index formula does not include an ethnicity-specific adjustment. However, published cut-off values have been derived from ethnically diverse populations, and researchers recommend applying population-specific thresholds when interpreting results. Some modified versions of the index incorporate ethnicity-adjusted waist circumference thresholds. Your healthcare provider can advise on the most appropriate interpretation for your specific background and population.

Can reducing waist circumference lower the ADO Index?

Yes. Since waist circumference is the only modifiable variable in the ADO formula (age and height change negligibly for adults), reducing waist circumference through lifestyle changes is the primary way to lower your ADO Index. Even modest reductions in waist circumference of 3-5 cm, achievable through dietary modification and increased physical activity, can meaningfully reduce the index and are associated with improvements in lipid profiles, blood pressure, and insulin sensitivity.

What lifestyle changes most effectively reduce waist circumference and ADO Index?

The most effective approaches combine reduced caloric intake with increased physical activity. Reducing refined carbohydrates and added sugars is particularly effective at reducing visceral fat. The Mediterranean diet, rich in vegetables, whole grains, olive oil, fish, and legumes, has strong evidence for reducing waist circumference and improving lipid profiles. Regular aerobic exercise (at least 150 minutes of moderate intensity per week) specifically targets visceral fat. Reducing alcohol intake also significantly reduces central adiposity.

Is the ADO Index useful for monitoring treatment response?

The ADO Index can serve as a crude proxy for treatment response in the absence of regular lipid testing, as reductions in waist circumference tend to correlate with improvements in lipid profiles. However, direct lipid measurement remains the gold standard for monitoring treatment efficacy, particularly for medication management. ADO Index monitoring may be most useful in community health settings or resource-limited environments where regular blood testing is not feasible.

What should I do if my ADO Index is in the high-risk range?

A high ADO Index does not diagnose dyslipidaemia but suggests elevated probability. You should consult a healthcare professional, who will likely recommend a fasting lipid panel blood test to directly measure cholesterol and triglyceride levels. Lifestyle modifications including dietary changes, increased physical activity, and alcohol reduction should be initiated regardless of laboratory results if central adiposity is present. If dyslipidaemia is confirmed, your doctor will advise on whether lifestyle changes alone or medication (such as statins or fibrates) is appropriate.

What is atherogenic dyslipidaemia?

Atherogenic dyslipidaemia refers specifically to the combination of elevated triglycerides, reduced HDL cholesterol, and a shift towards small, dense LDL particles. This lipid pattern is strongly associated with insulin resistance, central adiposity, and metabolic syndrome, and significantly increases the risk of atherosclerosis (arterial plaque formation) and cardiovascular disease. The ADO Index was primarily designed to detect this specific lipid pattern, which is closely linked to visceral fat accumulation.

How does menopause affect ADO Index interpretation in women?

Menopause is associated with a shift in fat distribution from peripheral to central depots, driven by declining oestrogen levels. This means postmenopausal women may have disproportionately higher visceral fat at a given waist circumference than premenopausal women, potentially increasing dyslipidaemia risk beyond what the standard sex factor of 0.8 captures. Postmenopausal women should be aware that their ADO Index may underestimate risk relative to their actual lipid status. Regular lipid testing is particularly important for postmenopausal women.

What blood tests are recommended alongside ADO Index screening?

When an elevated ADO Index prompts further investigation, a fasting lipid panel is the primary recommended blood test, measuring total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Additional tests may include fasting blood glucose or HbA1c (to assess diabetes risk), liver function tests (to evaluate non-alcoholic fatty liver disease, which commonly co-occurs with dyslipidaemia), and thyroid function (as hypothyroidism causes secondary dyslipidaemia). Your healthcare provider will determine which tests are appropriate based on your overall clinical presentation.

Can medications affect waist circumference and ADO Index?

Yes, several medications can increase central adiposity and thus the ADO Index. Corticosteroids (such as prednisolone) cause fat redistribution to central depots with chronic use. Some antipsychotic medications, antidepressants, and antiepileptic drugs are associated with weight gain and increased waist circumference. Insulin therapy can promote weight gain. If you are taking medications that may affect weight or fat distribution, discuss their metabolic effects with your prescribing physician.

How does the ADO Index relate to metabolic syndrome?

Metabolic syndrome is a cluster of cardiometabolic risk factors including central obesity, hypertriglyceridaemia, reduced HDL cholesterol, elevated blood pressure, and impaired fasting glucose. The ADO Index captures several components of this syndrome, particularly central adiposity (through waist circumference) and its associated lipid abnormalities. Individuals with high ADO Index scores are at elevated risk of meeting full metabolic syndrome criteria, which substantially increases cardiovascular and type 2 diabetes risk.

Is the ADO Index recommended by international medical organisations?

The ADO Index is primarily used in research and certain clinical settings rather than being a universally endorsed tool in international clinical guidelines. Major cardiovascular risk guidelines from organisations such as the American Heart Association (AHA), European Society of Cardiology (ESC), and World Heart Federation focus on direct lipid measurement and established risk calculators (such as the Pooled Cohort Equations or SCORE2). The ADO Index serves best as a low-cost, non-invasive screening adjunct where direct lipid testing is limited.

Can the ADO Index be used alongside other cardiovascular risk calculators?

Yes. The ADO Index complements rather than replaces established cardiovascular risk calculators. Tools such as the Framingham Risk Score, SCORE2 (European), QRISK3 (UK), or the ACC/AHA Pooled Cohort Equations estimate overall cardiovascular event risk and require laboratory data including total and HDL cholesterol. The ADO Index can serve as an initial non-invasive screen to identify individuals who may particularly benefit from formal cardiovascular risk assessment with blood testing.

What is the role of HDL cholesterol in cardiometabolic risk?

HDL (high-density lipoprotein) cholesterol facilitates reverse cholesterol transport — the process by which cholesterol is removed from arterial walls and returned to the liver for excretion. Low HDL cholesterol (below 1.0 mmol/L in men and 1.2 mmol/L in women) is an independent cardiovascular risk factor. Central adiposity and insulin resistance strongly suppress HDL production and increase HDL catabolism. The ADO Index’s ability to predict reduced HDL is particularly clinically relevant given HDL’s protective cardiovascular role.

Are there limitations to using height in the ADO formula?

Height appears in the ADO denominator, normalising waist circumference for body size. This is similar to the rationale behind waist-to-height ratio. The height adjustment helps account for the fact that taller individuals generally have larger absolute waist circumferences without necessarily having proportionally higher metabolic risk. One limitation is that height is fixed and does not change in adults, so it serves primarily as a scaling factor rather than an independent risk modifier.

Conclusion

The ADO Index is a validated, practical tool for identifying individuals at increased risk of dyslipidaemia based on simple anthropometric measurements. By incorporating waist circumference, age, height, and sex, it captures central adiposity more completely than BMI or waist circumference alone, and outperforms these simpler measures as a dyslipidaemia predictor in most validation studies.

As a screening tool, the ADO Index is most valuable in primary care, community health, and resource-limited settings where lipid testing is not immediately accessible. It should guide clinical decision-making about who requires formal lipid panel testing rather than replace blood-based lipid measurement.

High ADO Index scores should prompt lifestyle review, including dietary assessment, physical activity evaluation, and alcohol use discussion. When blood testing confirms dyslipidaemia, evidence-based management — spanning lifestyle modification to pharmacotherapy — can substantially reduce cardiovascular risk. Regular monitoring of waist circumference, alongside periodic lipid testing as recommended by a healthcare provider, supports effective long-term cardiometabolic risk management.

This calculator is provided for informational and educational purposes only. All results should be discussed with a qualified healthcare professional. Do not make medical decisions based solely on ADO Index results.